Schedule 13D ownership disclosure

Novus Therapeutics, Inc.

Security class unavailable · CUSIP: 67011N105

Event date: 2019-05-02

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
31.6000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-19-000328
Form type
SC 13D/A
Filer
Eledon Pharmaceuticals, Inc.
CIK
CIK 1404281
Filed
May 06, 2019
Reporting period
May 02, 2019
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub